Serum alkaline phosphatase changes predict survival independent of PSA changes in men with castration-resistant prostate cancer and bone metastasis receiving chemotherapy

Urologic Oncology: Seminars and Original Investigations

Volumn 30, Issue 5, 2012, Pages 607-613

  Sonpavde, Guru ^a   Pond, Gregory R ^b   Berry, William R ^c   de Wit, Ronald ^d   Armstrong, Andrew J ^e   Eisenberger, Mario A ^f   Tannock, Ian F ^g  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b MCMASTER UNIVERSITY   (Canada)

^c Cancer Centers of North Carolina   (United States)

^d ERASMUS MEDICAL CENTER   (Netherlands)

^e DUKE UNIVERSITY MEDICAL CENTER   (United States)

^f JOHNS HOPKINS UNIVERSITY   (United States)

^g PRINCESS MARGARET HOSPITAL   (Canada)

Author keywords

Bone metastasis; Castration resistant prostate cancer; Overall survival; PSA; Serum alkaline phosphatase

Indexed keywords

ALKALINE PHOSPHATASE; DOCETAXEL; MITOXANTRONE; PREDNISONE; PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ALKALINE PHOSPHATASE BLOOD LEVEL; ARTICLE; BONE METASTASIS; CANCER COMBINATION CHEMOTHERAPY; CANCER PROGNOSIS; CANCER SURVIVAL; CASTRATION RESISTANT PROSTATE CANCER; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE MARKER; HUMAN; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PRIORITY JOURNAL; RETROSPECTIVE STUDY;

ADULT; AGED; AGED, 80 AND OVER; ALKALINE PHOSPHATASE; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BONE NEOPLASMS; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; MITOXANTRONE; ORCHIECTOMY; OUTCOME ASSESSMENT (HEALTH CARE); PROGNOSIS; PROPORTIONAL HAZARDS MODELS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RETROSPECTIVE STUDIES; TAXOIDS; TIME FACTORS;

EID: 84866745304     PISSN: 10781439     EISSN: 18732496     Source Type: Journal    
DOI: 10.1016/j.urolonc.2010.07.002     Document Type: Article

References (28)

1. Petrylak D.P., Ankerst D.P., Jiang C.S., et al. Evaluation of prostate-specific antigen declines for surrogacy in patients treated on SWOG 99-16. J Natl Cancer Inst 2006, 98:516-521.
2. Armstrong A.J., Garrett-Mayer E., Ou Yang Y.C., et al. Prostate-specific antigen and pain surrogacy analysis in metastatic hormone-refractory prostate cancer. J Clin Oncol 2007, 25:3965-3970.
3. Hussain M., Goldman B., Tangen C., et al. Prostate-specific antigen progression predicts overall survival in patients with metastatic prostate cancer: Data from Southwest Oncology Group Trials 9346 (Intergroup Study 0162) and 9916. J Clin Oncol 2009, 27:2450-2456.
4. Armstrong AJ, Garrett-Mayer E, de Wit, R, et al. Prediction of survival following first-line chemotherapy in men with castration-resistant metastatic prostate cancer. Clin Cancer Res 16:203-11.
5. Scher H.I., Jia X., de Bono J.S., et al. Circulating tumor cells as prognostic markers in progressive, castration-resistant prostate cancer: A reanalysis of IMMC38 trial data. Lancet Oncol 2009, 10:233-239.
6. de Bono J.S., Scher H.I., Montgomery R.B., et al. Circulating tumor cells predict survival benefit from treatment in metastatic castration-resistant prostate cancer. Clin Cancer Res 2008, 14:6302-6309.
7. Bouchelouche K., Oehr P. Positron emission tomography and positron emission tomography/computerized tomography of urological malignancies: An update review. J Urol 2008, 179:34-45.
8. Armstrong A.J., Garrett-Mayer E.S., Yang Y.C., et al. A contemporary prognostic nomogram for men with hormone-refractory metastatic prostate cancer: A TAX327 study analysis. Clin Cancer Res 2007, 13:6396-6403.
9. Halabi S., Small E.J., Kantoff P.W., et al. Prognostic model for predicting survival in men with hormone-refractory metastatic prostate cancer. J Clin Oncol 2003, 21:1232-1237.
10. Xie W., Nakabayashi M., Regan M.M., et al. Higher prostate-specific antigen levels predict improved survival in patients with hormone-refractory prostate cancer who have skeletal metastases and normal serum alkaline phosphatase. Cancer 2007, 110:2709-2715.
11. Tannock I.F., de Wit R., Berry W.R., et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 2004, 351:1502-1512.
12. Berthold D.R., Pond G.R., Soban F., et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: Updated survival in the TAX 327 study. J Clin Oncol 2008, 26:242-245.
13. Lin D.Y., Fleming T.R., De Gruttola V. Estimating the proportion of treatment effect explained by a surrogate marker. Stat Med 1997, 16:1515-1527.
14. Alonso A., Molenberghs G., Burzykowski T., et al. Prentice's approach and the meta-analytic paradigm: A reflection on the role of statistics in the evaluation of surrogate endpoints. Biometrics 2004, 60:724-728.
15. Buyse M., Molenberghs G. Criteria for the validation of surrogate endpoints in randomized experiments. Biometrics 1998, 54:1014-1029.
16. Armstrong A.J., Tannock I.F., Wit R.D., et al. The development of risk groups in men with metastatic castration-resistant prostate cancer based on risk factors for PSA decline and survival. Eur J Cancer 2010, 46:517-525.
17. Wajsman Z., Chu T.M., Bross D., et al. Clinical significance of serum alkaline phosphatase isoenzyme levels in advanced prostatic carcinoma. J Urol 1978, 119:244-246.
18. Paulson D.F., Berry W.R., Cox E.B., et al. Treatment of metastatic endocrine-unresponsive carcinoma of the prostate gland with multiagent chemotherapy: Indicators of response to therapy. J Natl Cancer Inst 1979, 63:615-622.
19. Steineck G., Kelly W.K., Mazumdar M., et al. Acid phosphatase: Defining a role in androgen-independent prostate cancer. Urology 1996, 47:719-726.
20. Piovesan A., Berruti A., Torta M., et al. Comparison of assay of total and bone-specific alkaline phosphatase in the assessment of osteoblast activity in patients with metastatic bone disease. Calcif Tissue Int 1997, 61:362-369.
21. Galsky M.D., Scher H., Hummer A., et al. Analysis of the strength of association of multiple post-treatment time-dependent serum markers with survival in patients with castrate metastatic prostate cancer. Proc Am Soc Clin Oncol 2003, 22. [Abstract 1589].
22. Demers L.M., Costa L., Lipton A. Biochemical markers and skeletal metastases. Cancer 2000, 88:2919-2926.
23. Coleman R.E., Major P., Lipton A., et al. Predictive value of bone resorption and formation markers in cancer patients with bone metastases receiving the bisphosphonate zoledronic acid. J Clin Oncol 2005, 23:4925-4935.
24. Nilsson S., Franzen L., Parker C., et al. Bone-targeted radium-223 in symptomatic, hormone-refractory prostate cancer: A randomized, multicentre, placebo-controlled phase II study. Lancet Oncol 2007, 8:587-594.
25. Fizazi K., Lipton A., Mariette X., et al. Randomized phase II trial of denosumab in patients with bone metastases from prostate cancer, breast cancer, or other neoplasms after intravenous bisphosphonates. J Clin Oncol 2009, 27:1564-1571.
26. Higano C.S., Schellhammer P.F., Small E.J., et al. Integrated data from 2 randomized, double-blind, placebo-controlled, phase 3 trials of active cellular immunotherapy with sipuleucel-T in advanced prostate cancer. Cancer 2009, 115:3670-3679.
27. Lipton A., Cook R., Saad F., et al. Normalization of bone markers is associated with improved survival in patients with bone metastases from solid tumors and elevated bone resorption receiving zoledronic acid. Cancer 2008, 113:193-201.
28. Orriss I.R., Key M.L., Colston K.W., et al. Inhibition of osteoblast function in vitro by aminobisphosphonates. J Cell Biochem 2009, 106:109-118.